Perseus Proteomics Inc. Logo

Perseus Proteomics Inc.

Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.

4882 | T

Overview

Corporate Details

ISIN(s):
JP3836800007
LEI:
Country:
Japan
Address:
目黒区駒場四丁目7番6号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perseus Proteomics Inc. is a drug discovery biotechnology company founded in 2001 as a venture from the University of Tokyo. The company focuses on creating novel antibody-based therapeutics to treat cancer and other diseases, utilizing its proprietary and unique antibody technologies. Its business operations are structured around three core segments: Drug Discovery, which develops its pipeline of potential antibody drugs; Antibody Research Support Services for partner institutions; and the direct sale of antibody products and diagnostic reagents, such as ELISA kits. The company's mission is to contribute to global healthcare by developing innovative treatments for people suffering from diseases worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:32
Registration Form
確認書
Japanese 8.2 KB
2025-11-14 07:32
Interim Report
半期報告書-第26期(2025/04/01-2026/03/31)
Japanese 160.8 KB
2025-06-27 09:28
Post-Annual General Meeting Information
臨時報告書
Japanese 25.9 KB
2025-06-27 08:34
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 08:33
Registration Form
訂正有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2025-06-27 08:33
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 08:32
Annual Report
訂正有価証券報告書-第23期(2022/04/01-2023/03/31)
Japanese 1.5 MB
2025-06-27 08:32
Governance Information
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.4 KB
2025-06-27 08:31
Registration Form
確認書
Japanese 8.1 KB
2025-06-27 08:31
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 2.6 MB
2025-05-21 08:31
Regulatory News Service
臨時報告書
Japanese 20.2 KB
2024-11-14 07:34
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 07:34
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 163.4 KB
2024-06-20 07:40
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-06-20 07:34
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Perseus Proteomics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perseus Proteomics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perseus Proteomics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.